Literature DB >> 9613999

Treatment of human enterovirus infections.

H A Rotbart1, J F O'Connell, M A McKinlay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9613999     DOI： 10.1016/s0166-3542(97)00068-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  7 in total

Review 1.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 2.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

3.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

Review 4.  Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.

Authors:  Henry Fechner; Sandra Pinkert; Anja Geisler; Wolfgang Poller; Jens Kurreck
Journal:  Molecules       Date:  2011-10-11       Impact factor: 4.411

5.  Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1.

Authors:  Chee Wah Tan; Yoke Fun Chan; Kooi Mow Sim; Eng Lee Tan; Chit Laa Poh
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

6.  Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16.

Authors:  James T Kelly; Luigi De Colibus; Lauren Elliott; Elizabeth E Fry; David I Stuart; David J Rowlands; Nicola J Stonehouse
Journal:  Antiviral Res       Date:  2015-10-30       Impact factor: 5.970

Review 7.  Treatment of respiratory virus infections.

Authors:  Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2006-02-14       Impact factor: 5.970
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.